Sulfonated Aromatic Molecules as Allosteric Cathepsin G Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for human cathepsin G (CatG) have limitations, such as high risk of bleeding with heparin derivatives and lack of effective allosteric inhibitors with minimal bleeding risk, which restricts their clinical utility in treating inflammatory diseases like periodontitis, rheumatoid arthritis, and others.
Innovation Solution
Development of sulfonated aromatic molecules acting as allosteric inhibitors of CatG, which inhibit the enzyme in a salt-dependent manner with high efficacy and selectivity, protecting extracellular matrix components like laminin and fibronectin from degradation without significant bleeding risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heparin derivatives are used as CatG inhibitors, then inhibition efficacy is improved, but bleeding risk increases
Solution Approach 1:
The invention changes the chemical structure parameters of CatG inhibitors by introducing sulfonated aromatic groups and phosphonate groups, which fundamentally alter the interaction mechanism with CatG. This structural modification enables potent inhibition through a different binding mode that does not trigger the bleeding pathway associated with heparin derivatives.
Solution Approach 2:
The patent employs a small molecule intermediary compound that mediates CatG inhibition through a mechanism distinct from heparin. This intermediary compound binds to CatG and blocks its activity without activating the anticoagulant cascade that leads to bleeding, thus providing a safer inhibition pathway.
2Reliability
If conventional CatG inhibitors are used, then inflammation treatment is achieved, but side effects increase
Solution Approach 1:
The invention modifies the chemical parameters of CatG inhibitors by incorporating sulfonated aromatic structures with specific charge distributions and spatial arrangements. These parameter changes enable selective binding to CatG while minimizing non-specific interactions that cause side effects, achieving effective inflammation treatment with improved safety.
Solution Approach 2:
The patent introduces local quality variations in the inhibitor structure through sulfonated groups at specific positions on aromatic rings. These localized functional groups provide targeted interaction with CatG's active site or allosteric regions, enhancing specificity and reducing off-target effects that lead to side effects.
Data Source
AI summary
The present disclosure relates to methods of use and treatment by inhibition of Cathepsin G by compounds described herein.